Lubiprostone phase 3 long-term safety study

Multi-center, open-label safety study of lubiprostone for the treatment of chronic idiopathic constipation (CIC)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220731

Enrollment

200

Registered

2009-05-12

Start date

2009-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic idiopathic constipation

Interventions

investigational material(s) Generic name etc : Lubiprostone INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for Inv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: history of fewer than three spontaneous bowl movements (SBMs) per week for at least six months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Safety (Adverse events, Clinical laboratory tests, and Physical examinations)	—

Secondary

Measure	Time frame
Efficacy (change in SBMs at the end of the first week of treatment, etc.)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026